The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to the impact of this drug on disease-free survival. However, the ABCSG-18 study has achieved its primary goal: prevention of clinical fractures. Therefore, the protective role of Denosumab on bone fragility induced by estrogen deprivation, already demonstrated in post-menopausal women, has been validated in the breast cancer setting.
Adjuvant denosumab for early breast cancer-Evidence and controversy
Moretti, Laura;Richelmi, Laura;Cosentini, Deborah;Pedersini, Rebecca;Grisanti, Salvatore;Amoroso, Vito;Berruti, Alfredo;Laganà, Marta
2024-01-01
Abstract
The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to the impact of this drug on disease-free survival. However, the ABCSG-18 study has achieved its primary goal: prevention of clinical fractures. Therefore, the protective role of Denosumab on bone fragility induced by estrogen deprivation, already demonstrated in post-menopausal women, has been validated in the breast cancer setting.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Adjuvant denosumab for early breast cancer-Evidence and controversy.pdf
accesso aperto
Descrizione: Adjuvant denosumab for early breast cancer
Tipologia:
Full Text
Licenza:
DRM non definito
Dimensione
1.57 MB
Formato
Adobe PDF
|
1.57 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
